文献速递急性肾损伤血液净化与透析

透析依赖型急性肾损伤恢复期患者对比剂暴露后的肾脏结局:目标试验模拟研究

Kidney Outcomes After Contrast Exposure in Patients Recovering From Dialysis-Requiring Acute Kidney Injury: A Target Trial Emulation Study.
PubMed 文献 · Am J Kidney Dis · 2026-06-19

结果显示,对比剂暴露与再次透析治疗风险(SHR 1.37,95%CI 1.20-1.56)和持续性肾功能障碍风险(SHR 1.11,95%CI 1.01-1.23)升高独立相关,且在独立多医院队列中得到验证。

要点

  • AKI-D恢复后30天内接受对比增强CT与再次透析风险增加独立相关(SHR 1.37)。
  • 对比剂暴露亦与持续性肾功能障碍风险轻度升高相关(SHR 1.11)。
  • 对比剂暴露后肾脏事件风险在eGFR低于36 mL/min/1.73 m²时最高。

核心结论

  • 在近期从AKI-D恢复且不再依赖透析的成人中,碘对比剂暴露与再次透析治疗和持续性肾功能障碍风险增加相关。

研究设计与样本

  • 采用目标试验模拟框架下的逆概率治疗加权(IPTW)比较静脉碘对比剂暴露与未暴露者。
  • 共纳入23,263例从AKI-D透析后恢复的患者,平均年龄69.6岁,58.5%为男性。

主要发现

  • 1,551例(6.7%)在最初30天内接受了对比增强计算机断层扫描。
  • IPTW后,对比剂暴露与再次透析治疗风险升高独立相关(SHR 1.37,95%CI 1.20-1.56)。
  • IPTW后,对比剂暴露与持续性肾功能障碍风险升高独立相关(SHR 1.11,95%CI 1.01-1.23)。
  • 广义相加模型显示,接受对比剂的患者肾脏事件风险在AKI-D后eGFR低于36 mL/min/1.73 m²时最高,而未接受对比剂者为22.8 mL/min/1.73 m²。
  • 在1,195例AKI-D幸存者的独立多医院队列中进行外部验证,证实对比剂暴露后肾脏事件风险增加。

关键数值与推荐

  • 主要肾脏事件为再次接受透析治疗;次要事件为持续性肾功能障碍,定义为指数日期后1年时血清肌酐较AKI恢复后水平升高至少0.3 mg/dL或50%。

临床怎么用

  • 对于近期从AKI-D恢复且不再依赖透析的患者,应谨慎考虑碘对比剂的使用,尤其当eGFR较低时。

局限性

  • 观察性研究设计无法确定确切的因果推断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The impact of iodinated contrast media (ICM) on kidney outcomes remains debated, especially when used with patients recovering from acute kidney injury requiring dialysis (AKI-D). Despite apparent clinical recovery, these individuals may remain vulnerable to repeat kidney insults. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adults recovering from AKI-D were identified using Taiwan's National Health Insurance Research Database between January 2015 and December 2022. EXPOSURE: Intravenous ICM. OUTCOME: The primary kidney event was recurrent treatment with dialysis; the secondary was persistent kidney dysfunction, defined as at least 0.3 mg/dL or 50% increase in serum creatinine from post-AKI recovery levels at 1 year after index date. ANALYTICAL APPROACH: Observational analysis using inverse probability of treatment weighting (IPTW) within a target trial emulation framework to compare patients exposed to ICM with unexposed counterparts. RESULTS: Among 23,263 patients recovering from dialysis after AKI-D (mean age, 69.6 years; 58.5% men), 1,551 (6.7%) received contrast-enhanced computed tomography in the first 30 days. After IPTW, ICM was independently associated with a higher hazard of recurrent treatment with dialysis (subdistribution hazard ratio (SHR), 1.37 [95% CI, 1.20-1.56]) and persistent kidney dysfunction (SHR, 1.11 [95% CI, 1.01-1.23]). Generalized-additive modeling showed that the risk for kidney events was greatest when the estimated glomerular filtration rate (eGFR) after AKI-D fell below 36 mL/min/1.73 m2 in the patients who received contrast, compared with 22.8 mL/min/1.73 m2 in patients who did not. External validation in an independent, multihospital cohort of 1,195 AKI-D survivors confirmed the excess risk of kidney events after contrast exposure. LIMITATIONS: The observational nature of this study precludes definitive causal inference. CONCLUSIONS: Among adults recently recovering from AKI-D and no longer dependent on dialysis, ICM exposure was associated with an increased risk of a recurrent treatment with dialysis and persistent kidney dysfunction. These findings inform clinical management of these patients and the use of contrast in this high-risk population. PLAIN-LANGUAGE SUMMARY: The effects of iodinated contrast on kidney function remain controversial and are even less well understood in patients recovering from acute kidney injury requiring dialysis (AKI-D). In this nationwide observational study using a target trial emulation framework, we evaluated adults with AKI-D whose recovery permitted discontinued dialysis. We found that patients who underwent contrast-enhanced computed tomography scans within 30 days of dialysis cessation were more likely to require dialysis again and to develop persistent kidney dysfunction compared with those who did not receive contrast. These findings suggest that kidney function may remain vulnerable after apparent recovery and support careful consideration of contrast use in this high-risk population.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lin LC, Tao-Min Huang T, Wu YT, et al. Kidney Outcomes After Contrast Exposure in Patients Recovering From Dialysis-Requiring Acute Kidney Injury: A Target Trial Emulation Study. Am J Kidney Dis. 2026. PMID: 42320580. doi:10.1053/j.ajkd.2026.03.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。